Researcher Profile

Kevin A. David, MD

Assistant Professor of Medicine, Medical Oncology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08901-1914

Phone: (732) 235-2045

Assistant: Maribel Borrero
(732) 235-6272

Research Program Alignments

Membership Type: Associate - CCSG

Research Interests

  • The role of autophagy inhibition in treating acute myeloid leukemia in ther elderly
  • Developing clinical trials in Hodgkin lymphoma and non-Hodgkins lymphoma.

Selected Publications

Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM.  2011. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 185(5):1631-6.

Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K, Gordon LI. 2010. Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata.  Clin Cancer Res. 16(19):4755-68.

Bhalla S, Gordon LI, David K, Prachand S, Singh AT, Yang S, Winter JN, Guo D, O'Halloran T, Platanias LC, Evens AM. 2010. Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. Br J Haematol 150(3):365-9.

David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. 2010. Phase I Trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.  Cancer Biol Ther 9(9): 678-684.

Evens AM, David KA, Helenowski IB, Nelson B, Kaufman D, Kircher S, Gimelfarb A, Hattersley E, Mauro L, Jovanovic B, Chadburn AM, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory SA, Gordon LI, Shammo JM, Smith S, Smith SM. Multicenter Analysis of 80 Solid Organ Transplant Recipients with Posttransplantation Lymphoproliferative Disease (PTLD):  Outcomes and Prognostic Factors in the Modern Era. J Clin Onc  28(6):1038-46

Joshi S, Kaur S, Redig AJ, Goldsborough K, David K, Ueda T, Watanabe-Fukunaga R, Baker DP, Fish EN, Fukunaga R, Platanias LC. 2009.  Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses. PNAS. 106: 12097-102.

Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM. 2009. The Histone Deacetylase Inhibitor PCI-24781Induces Caspase and ROS-Dependent Apoptosis Through NF-ĸB Mechanisms and is Synergistic with Bortezomib in Lymphoma Cells.  Clin Cancer Res. 15(10): 3354-3365.
David KA, Mallin K, Milowsky MI, Ritchey J, Carroll P, Nanus DM.  2009. Surveillance of Urothelial Carcinoma:Stage and Grade Migration, 1993-2005 and Survival Trends, 1993-2000. Cancer 115(7):1435-47.

David KA, Mauro L, Evens AM. 2007. Relapsed and Refractory Hodgkin Lymphoma: Transplantation Strategies and Novel Therapeutic Options. Curr Treat Options Oncol. 8(5): 352-374.

David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. 2007. Perioperative chemotherapy treatment patterns in stage III transitional cell carcinoma: a report from the National Cancer Data Base. J Urol 178(2): 451-454.

David KA, Milowsky MI, Nanus DM. 2006. Chemotherapy for non-clear-cell renal cell carcinoma. Clin Genitourin Cancer. 4(4):263-8.

David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH. 2006. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clin Genitourin Cancer. 4(4): 249-56.

David KA, Picus J. 2005. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 28(3):277-80.

The content for this Research Profile is maintained by Paul Novembre (